Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum

Rebecca Zhu, Fangfang Liu, Gabriella Grisotti, Javier Pérez-Irizarry, Charles H. Cha, Caroline H. Johnson, Daniel J. Boffa, Dale Han, Kimberly L. Johung, Yawei Zhang, Sajid A. Khan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Colon and rectal gastrointestinal stromal tumors (GISTs) are rare and poorly characterized. Because the majority of treatment guidelines for GISTs are extrapolated from tumors of gastric and small bowel origin, our aim was to better characterize the unique clinicopathologic features and prognostic factors of colon and rectal GISTs to guide clinical care. Methods: The National Cancer Data Base (NCDB) was queried from 2006 to 2013 for cases of GISTs in the stomach, colon, and rectum. Patient demographics, clinical characteristics, and survival were compared. Results: A total of 11,302 gastric GISTs were compared to 398 colon and 393 rectal GISTs. After propensity matching, compared to gastric GISTs, rectal GISTs had improved overall survival (HR =0.695, P=0.0264), while colon GISTs had worse overall survival (HR =1.6, P=0.0005). Surgical treatment for rectal GISTs was more likely to be local excision compared to colonic GISTs (51.1% vs. 8.4%, P<0.0001). Colon and gastric GISTs were less likely to receive systemic therapy compared to rectal GISTs (34.2% vs. 34.0% vs. 55.2%, P<0.0001). Adjuvant systemic therapy conveyed a survival advantage to rectal GISTs (HR =0.47, P=0.042) but not colon GISTs. There was a negative impact of adjuvant therapy on survival for colon GISTs <5 cm (HR =3.41, P=0.032). Conclusions: Patients with rectal GISTs live longer than those with colon and gastric GISTs, and adjuvant therapy prolongs their survival. Many patients with colon GISTs are treated with adjuvant therapy despite a detrimental effect on survival. Tumor biology of colon and rectal GISTs needs to be better studied to tailor treatment.

Original languageEnglish (US)
Pages (from-to)231-240
Number of pages10
JournalJournal of Gastrointestinal Oncology
Volume9
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Rectum
Colon
Rectal Neoplasms
Stomach
Survival
Therapeutics
Neoplasms

Keywords

  • Adjuvant therapy
  • Colon
  • Gastrointestinal stromal tumors (GISTs)
  • Rectum
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Zhu, R., Liu, F., Grisotti, G., Pérez-Irizarry, J., Cha, C. H., Johnson, C. H., ... Khan, S. A. (2018). Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum. Journal of Gastrointestinal Oncology, 9(2), 231-240. https://doi.org/10.21037/jgo.2017.11.12

Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum. / Zhu, Rebecca; Liu, Fangfang; Grisotti, Gabriella; Pérez-Irizarry, Javier; Cha, Charles H.; Johnson, Caroline H.; Boffa, Daniel J.; Han, Dale; Johung, Kimberly L.; Zhang, Yawei; Khan, Sajid A.

In: Journal of Gastrointestinal Oncology, Vol. 9, No. 2, 01.04.2018, p. 231-240.

Research output: Contribution to journalArticle

Zhu, R, Liu, F, Grisotti, G, Pérez-Irizarry, J, Cha, CH, Johnson, CH, Boffa, DJ, Han, D, Johung, KL, Zhang, Y & Khan, SA 2018, 'Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum', Journal of Gastrointestinal Oncology, vol. 9, no. 2, pp. 231-240. https://doi.org/10.21037/jgo.2017.11.12
Zhu, Rebecca ; Liu, Fangfang ; Grisotti, Gabriella ; Pérez-Irizarry, Javier ; Cha, Charles H. ; Johnson, Caroline H. ; Boffa, Daniel J. ; Han, Dale ; Johung, Kimberly L. ; Zhang, Yawei ; Khan, Sajid A. / Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum. In: Journal of Gastrointestinal Oncology. 2018 ; Vol. 9, No. 2. pp. 231-240.
@article{504202ff85bb47a8bb438250380e3de7,
title = "Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum",
abstract = "Background: Colon and rectal gastrointestinal stromal tumors (GISTs) are rare and poorly characterized. Because the majority of treatment guidelines for GISTs are extrapolated from tumors of gastric and small bowel origin, our aim was to better characterize the unique clinicopathologic features and prognostic factors of colon and rectal GISTs to guide clinical care. Methods: The National Cancer Data Base (NCDB) was queried from 2006 to 2013 for cases of GISTs in the stomach, colon, and rectum. Patient demographics, clinical characteristics, and survival were compared. Results: A total of 11,302 gastric GISTs were compared to 398 colon and 393 rectal GISTs. After propensity matching, compared to gastric GISTs, rectal GISTs had improved overall survival (HR =0.695, P=0.0264), while colon GISTs had worse overall survival (HR =1.6, P=0.0005). Surgical treatment for rectal GISTs was more likely to be local excision compared to colonic GISTs (51.1{\%} vs. 8.4{\%}, P<0.0001). Colon and gastric GISTs were less likely to receive systemic therapy compared to rectal GISTs (34.2{\%} vs. 34.0{\%} vs. 55.2{\%}, P<0.0001). Adjuvant systemic therapy conveyed a survival advantage to rectal GISTs (HR =0.47, P=0.042) but not colon GISTs. There was a negative impact of adjuvant therapy on survival for colon GISTs <5 cm (HR =3.41, P=0.032). Conclusions: Patients with rectal GISTs live longer than those with colon and gastric GISTs, and adjuvant therapy prolongs their survival. Many patients with colon GISTs are treated with adjuvant therapy despite a detrimental effect on survival. Tumor biology of colon and rectal GISTs needs to be better studied to tailor treatment.",
keywords = "Adjuvant therapy, Colon, Gastrointestinal stromal tumors (GISTs), Rectum, Survival",
author = "Rebecca Zhu and Fangfang Liu and Gabriella Grisotti and Javier P{\'e}rez-Irizarry and Cha, {Charles H.} and Johnson, {Caroline H.} and Boffa, {Daniel J.} and Dale Han and Johung, {Kimberly L.} and Yawei Zhang and Khan, {Sajid A.}",
year = "2018",
month = "4",
day = "1",
doi = "10.21037/jgo.2017.11.12",
language = "English (US)",
volume = "9",
pages = "231--240",
journal = "Journal of Gastrointestinal Oncology",
issn = "2078-6891",
publisher = "Pioneer Bioscience Publishing Company (PBPC)",
number = "2",

}

TY - JOUR

T1 - Distinctive features of gastrointestinal stromal tumors arising from the colon and rectum

AU - Zhu, Rebecca

AU - Liu, Fangfang

AU - Grisotti, Gabriella

AU - Pérez-Irizarry, Javier

AU - Cha, Charles H.

AU - Johnson, Caroline H.

AU - Boffa, Daniel J.

AU - Han, Dale

AU - Johung, Kimberly L.

AU - Zhang, Yawei

AU - Khan, Sajid A.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Colon and rectal gastrointestinal stromal tumors (GISTs) are rare and poorly characterized. Because the majority of treatment guidelines for GISTs are extrapolated from tumors of gastric and small bowel origin, our aim was to better characterize the unique clinicopathologic features and prognostic factors of colon and rectal GISTs to guide clinical care. Methods: The National Cancer Data Base (NCDB) was queried from 2006 to 2013 for cases of GISTs in the stomach, colon, and rectum. Patient demographics, clinical characteristics, and survival were compared. Results: A total of 11,302 gastric GISTs were compared to 398 colon and 393 rectal GISTs. After propensity matching, compared to gastric GISTs, rectal GISTs had improved overall survival (HR =0.695, P=0.0264), while colon GISTs had worse overall survival (HR =1.6, P=0.0005). Surgical treatment for rectal GISTs was more likely to be local excision compared to colonic GISTs (51.1% vs. 8.4%, P<0.0001). Colon and gastric GISTs were less likely to receive systemic therapy compared to rectal GISTs (34.2% vs. 34.0% vs. 55.2%, P<0.0001). Adjuvant systemic therapy conveyed a survival advantage to rectal GISTs (HR =0.47, P=0.042) but not colon GISTs. There was a negative impact of adjuvant therapy on survival for colon GISTs <5 cm (HR =3.41, P=0.032). Conclusions: Patients with rectal GISTs live longer than those with colon and gastric GISTs, and adjuvant therapy prolongs their survival. Many patients with colon GISTs are treated with adjuvant therapy despite a detrimental effect on survival. Tumor biology of colon and rectal GISTs needs to be better studied to tailor treatment.

AB - Background: Colon and rectal gastrointestinal stromal tumors (GISTs) are rare and poorly characterized. Because the majority of treatment guidelines for GISTs are extrapolated from tumors of gastric and small bowel origin, our aim was to better characterize the unique clinicopathologic features and prognostic factors of colon and rectal GISTs to guide clinical care. Methods: The National Cancer Data Base (NCDB) was queried from 2006 to 2013 for cases of GISTs in the stomach, colon, and rectum. Patient demographics, clinical characteristics, and survival were compared. Results: A total of 11,302 gastric GISTs were compared to 398 colon and 393 rectal GISTs. After propensity matching, compared to gastric GISTs, rectal GISTs had improved overall survival (HR =0.695, P=0.0264), while colon GISTs had worse overall survival (HR =1.6, P=0.0005). Surgical treatment for rectal GISTs was more likely to be local excision compared to colonic GISTs (51.1% vs. 8.4%, P<0.0001). Colon and gastric GISTs were less likely to receive systemic therapy compared to rectal GISTs (34.2% vs. 34.0% vs. 55.2%, P<0.0001). Adjuvant systemic therapy conveyed a survival advantage to rectal GISTs (HR =0.47, P=0.042) but not colon GISTs. There was a negative impact of adjuvant therapy on survival for colon GISTs <5 cm (HR =3.41, P=0.032). Conclusions: Patients with rectal GISTs live longer than those with colon and gastric GISTs, and adjuvant therapy prolongs their survival. Many patients with colon GISTs are treated with adjuvant therapy despite a detrimental effect on survival. Tumor biology of colon and rectal GISTs needs to be better studied to tailor treatment.

KW - Adjuvant therapy

KW - Colon

KW - Gastrointestinal stromal tumors (GISTs)

KW - Rectum

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85045437259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045437259&partnerID=8YFLogxK

U2 - 10.21037/jgo.2017.11.12

DO - 10.21037/jgo.2017.11.12

M3 - Article

AN - SCOPUS:85045437259

VL - 9

SP - 231

EP - 240

JO - Journal of Gastrointestinal Oncology

JF - Journal of Gastrointestinal Oncology

SN - 2078-6891

IS - 2

ER -